Researchers developing microneedle technology for painless vaccinations
By
Ryner Lai
May 11, 2023
British researchers say they are developing microneedle technology for vaccine delivery, potentially eliminating the need for painful vaccine injections.
Disparities in COVID-19 vaccination identified among healthcare employees
Jun 16, 2021
Vaccination was least likely among clinical nurses, support staff and workers at skilled nursing and rehabilitation facilities.
COVID-19 hospitalization rates higher in unvaccinated during omicron
Sep 14, 2022
Hospitalization rates were 2.5 times higher for vaccinated patients without booster versus those with a booster.
Just 20 states reached Biden’s July 4 vaccination goal
Jul 06, 2021
Parts of the South, Southwest and Midwest starting to see surges, particularly Florida, with about 17% of all new cases reported there.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Flu vaccine may protect against adverse events after SARS-CoV-2
Aug 17, 2021
Individuals who had received a flu vaccination had lower risks for sepsis, stroke and deep vein thromboses as well as emergency department and ICU admissions
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Rates of COVID-19, severe illness lower with BNT162b2 booster dose
Dec 09, 2021
A second study shows a reduction in the rate of death due to COVID-19 with a booster dose of BNT162b2 (Pfizer–BioNTech).
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.